Loading stock data…
CLPT
$13.59+0.21 (+1.57%)
After Hours$13.60+0.01 (+0.07%)· Last close Jun 9
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ClearPoint Neuro, Inc. in the Healthcare sector is trading at $13.59. Wall Street consensus targets $22.00 (3 analysts), implying a +61.9% move over the next 12 months. The stock is currently 55% below its 52-week high of $30.10, remaining 4.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +61.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$13.59
Potential Downside
0%
Whystock Fair Value$13.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint sy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-154.27%
Volume
Today's trading volume
323,681
Recent News
How The ClearPoint Neuro (CLPT) Narrative Is Shifting On Partnerships Valuation And FDA Risks
ClearPoint Neuro’s fair value estimate has been trimmed from US$25.00 to US$22.00, roughly a 12% reduction in the modeled price target. Analysts link this reset to a balance of optimism around more than 60 biopharma partnerships and expedited intracranial programs, as well as caution tied to recent FDA feedback and its impact on revenue assumptions. As you read on, you will see how this evolving narrative could influence how you track the stock and its key milestones over time. Analyst Price...
ClearPoint Neuro Inc (CLPT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth
ClearPoint Neuro Inc (CLPT) reports a 43% revenue increase and strategic advancements despite rising operational costs.
ClearPoint Neuro Q1 Earnings Call Highlights
ClearPoint Neuro (NASDAQ:CLPT) reported record first-quarter 2026 revenue and reaffirmed its full-year outlook, as management highlighted growth in its legacy neurosurgical device business and early contributions from the recently acquired IRRAflow product line. Chief Executive Officer Joe Burnett
Compared to Estimates, ClearPoint Neuro (CLPT) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for ClearPoint Neuro (CLPT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ClearPoint Neuro Q1 2026 Earnings Call Transcript
ClearPoint Neuro (NASDAQ:CLPT) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. View the webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=IjzOoM7l Summary ClearPoint Neuro reported record revenue of $12.1 million for Q1 2026, with a 43% growth rate drive